Activities (5,000,000) -
------------ ------------
Cash Flows From Financing
Activities:
Proceeds from common stock option
exercises - 31,267
Merger, net (3,831,357)
Net proceeds from registered direct
offerings 13,803,684 13,798,183
------------ ------------
Net Cash Provided By Financing
Activities 9,972,327 13,829,450
------------ ------------
Net Change in Cash and Cash
Equivalents (23,229,048) (15,230,762)
Cash and Cash Equivalents --
Beginning of Year 26,480,928 41,711,690
------------ ------------
Cash and Cash Equivalents -- End of
Year $ 3,251,880 $ 26,480,928
============ ============
Supplemental Disclosures of Cash
Flow Information and Non-cash
Activities:
IPR&D Milestones included in License
Payable $ 28,400,000 $ -
Prepaid Manufacturing transferred to
Inventory $ 6,134,895 $ -
Reflects a 1-for-25 reverse stock split effective November 25, 2024.
View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-inc-reports-fiscal-full-year-2024-financial-results-and-provides-business-update-302339718.html
SOURCE Citius Pharmaceuticals, Inc.
(END) Dow Jones Newswires
December 27, 2024 17:00 ET (22:00 GMT)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.